A coalition of over 100 cancer groups is urging Congress to include the Clinical Treatment Act (HR-913) in an upcoming health care extenders package, scheduled to be considered this spring.
This story begins our occasional series looking back at the history of oncology since the signing of the National Cancer Act of 1971. The Cancer Letter was founded in 1973.
Explaining his decision to grant clemency to the financier Michael Milken, President Trump spoke thus:
FDA has granted approval Pemfexy, a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin and other indications.
Bristol-Myers Squibb Co. said FDA has accepted for Priority Review its Biologics License Application for lisocabtagene maraleucel (liso-cel), the company's autologous anti-CD19 CAR T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. The FDA has set a Prescription Drug User Fee Act goal date of Aug. 17.
FDA has accepted Seattle Genetics' new drug application for its investigational medicine tucatinib for Priority Review.
FDA has granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.
Myriad Genetics has submitted a supplementary premarket approval application to FDA for its myChoice CDx test to help identify women with advanced ovarian cancer who are potential candidates for maintenance therapy with Lynparza (olaparib) in combination with bevacizumab.
Patients who underwent a stem cell transplant and received the Triplex vaccine to prevent a type of herpes virus, cytomegalovirus, from duplicating out of control were 50% less likely to develop health complications related to the virus than patients who did not take Triplex, according to a City of Hope-led study published today in Annals of Internal Medicine.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment.
